Drug Combo Shows Promise Against Advanced Head and Neck Cancer
MONDAY, April 3, 2023 (HealthDay News) — An experimental targeted drug could provide a fresh chance for people with recurring head and neck cancer that has grown resistant to other treatments, a new clinical trial says. Ficlatuzumab used in combination with the already approved targeted drug cetuximab (Erbitux) significantly improvedContinue Reading